1 completed, 1 terminated. 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Completed 1, Terminated 1 |
Follow TG-1801: new trials by email Literature Review of TG-1801 trials Research Report on TG-1801
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of TG-1801 Alone or in Combination With Ublituximab in Subjects With B-Cell Lymphoma or Chronic Lymphocytic Leukemia TG-1801, Ublituximab - CLL, SLL | Phase 1 | Terminated | TG Therapeutics, Inc. | 21 | 2021-04-28 | 2024-07-31 |
| Study of TG-1801 in Subjects With B-Cell Lymphoma TG-1801, Ublituximab - B-Cell Lymphoma | Phase 1 | Completed | TG Therapeutics, Inc. | 50 | 2019-03-05 | 2024-04-08 |
Lymphoma, B-Cell (1) · Lymphoma, B-Cell, Marginal Zone (1) · Lymphoma, Follicular (1) · Recurrence (1)
Australia (1) · United States (1)